RxDoctor Payments DataLook up a doctor →

Muhammad Irfan, MD

Internal Medicine · Tomball, TXNPI 1972570489

Payments from drug & device makers

$30,623,985in general payments, 2019–2025

Across 7,429 payments — averaging $4122.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$18.5M
  • Pfizer$4.7M
  • Emergent Biosolutions Inc.$999K
  • Johnson & Johnson$962K
  • Bavarian Nordic A/s$927K
  • AbbVie$771K
  • plus $3.8M from 49 others
$50,665in research payments, 2019–2025

Across 17 payments — averaging $2980.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$48K
  • Sanofi US Services Inc.$2K
  • Eli Lilly$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.5,496$18,483,954
Pfizer362$4,658,807
Emergent Biosolutions Inc.98$999,494
Johnson & Johnson108$962,171
Bavarian Nordic A/s236$926,984
AbbVie(2 entities)271$770,568
Biohaven Pharmaceuticals, Inc.90$669,268
Amgen18$490,452
Sanofi Pasteur Inc.56$436,458
Novavax Inc10$360,274
Eli Lilly7$336,352
GSK52$330,526
Seqirus USA Inc292$306,203
Astrazeneca UK Limited4$303,690
AstraZeneca31$252,834
Biohaven Pharmaceutical Holding Company Ltd.110$192,332
Lexicon Pharmaceuticals, Inc.25$86,983
Sanofi US Services Inc.5$37,398
Shire North American Group Inc7$8,390
Ferring International Pharmascience Center US6$6,730
Takeda Pharmaceuticals U.S.A., Inc.1$1,320
Novo Nordisk25$506
Amarin Pharma, Inc.18$364
Astellas Pharma US Inc4$278
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$219
Lilly USA, LLC10$189
Dexcom, Inc.8$147
Bayer8$135
Abbott8$127
Esperion Therapeutics, Inc.3$69
Radius Health, Inc.2$68
Kowa Pharmaceuticals America, Inc.4$60
Lundbeck LLC2$56
Philips North America LLC3$47
Mylan Specialty L.p.2$45
Eisai Inc.2$45
Merck3$42
Sanofi-aventis U.S. LLC3$36
UCB, Inc.1$32
Inspire Medical Systems, Inc.1$29
Novartis2$28
Valeritas, Inc.1$27
Genentech USA, Inc.2$26
Sunovion Pharmaceuticals Inc.2$22
Xeris Pharmaceuticals, Inc.1$22
E.r. Squibb & Sons, L.L.C.1$21
Phathom Pharmaceuticals, Inc.1$20
Corcept Therapeutics1$19
Daiichi Sankyo Inc.1$19
Avanir Pharmaceuticals, Inc.1$19
Neurocrine Biosciences, Inc.1$18
Exact Sciences1$17
Medtronic1$15
Boehringer Ingelheim1$14
Otsuka America Pharmaceutical, Inc.1$14

How this compares

$30,623,985 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas →

Medicare billing

Part B allowed, 2024
$334,622
Medicare patients
489
Services billed
4,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Tomball

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →